This study successfully established an ApoB48 KO mouse model using CRISPR/Cas9 technology, which can improve various metabolic disorders caused by HFD, including increased fat content, hyperlipidaemia, insulin resistance, AS development, and intestinal tissue destruction. Here, APOB is linked to metabolic disease.